(Q48665941)

English

A record of 1320 suspect, deferasirox-related, patient deaths reported in 2009: insufficient toxicity testing, low efficacy and lack of transparency may endanger the lives of iron loaded patients

scientific article published in January 2011

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/21599442

A record of 1320 suspect, deferasirox-related, patient deaths reported in 2009: insufficient toxicity testing, low efficacy and lack of transparency may endanger the lives of iron loaded patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/21599442

George J Kontoghiorghes

1

object named as

George J Kontoghiorghes

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/21599442

publication date

1 January 2011

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/21599442

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/21599442

35

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/21599442

3

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/21599442

301-311

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/21599442

Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox

1 reference

https://api.crossref.org/works/10.3109%2F03630269.2011.576906

21 January 2018

Light and shadows in the iron chelation treatment of haematological diseases

1 reference

https://api.crossref.org/works/10.3109%2F03630269.2011.576906

21 January 2018

Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders.

1 reference

https://api.crossref.org/works/10.3109%2F03630269.2011.576906

21 January 2018

Transparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwide

1 reference

https://api.crossref.org/works/10.3109%2F03630269.2011.576906

21 January 2018

Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorption

1 reference

https://api.crossref.org/works/10.3109%2F03630269.2011.576906

21 January 2018

Do we need more iron-chelating drugs?

1 reference

https://api.crossref.org/works/10.3109%2F03630269.2011.576906

21 January 2018

Pharmacokinetics, distribution, metabolism, and excretion of deferasirox and its iron complex in rats

1 reference

https://api.crossref.org/works/10.3109%2F03630269.2011.576906

21 January 2018

The efficacy of deferiprone on tissues aluminum removal and copper, zinc, manganese level in rabbits

1 reference

https://api.crossref.org/works/10.3109%2F03630269.2011.576906

21 January 2018

Drug interactions during therapy with three major groups of antimicrobial agents

1 reference

https://api.crossref.org/works/10.3109%2F03630269.2011.576906

21 January 2018

Inhibition of iron uptake by phytic acid, tannic acid, and ZnCl2: studies using an in vitro digestion/Caco-2 cell model

1 reference

https://api.crossref.org/works/10.3109%2F03630269.2011.576906

21 January 2018

Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities

1 reference

https://api.crossref.org/works/10.3109%2F03630269.2011.576906

21 January 2018

Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases

1 reference

https://api.crossref.org/works/10.3109%2F03630269.2011.576906

21 January 2018

Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations

1 reference

https://api.crossref.org/works/10.3109%2F03630269.2011.576906

21 January 2018

Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy

1 reference

https://api.crossref.org/works/10.3109%2F03630269.2011.576906

21 January 2018

Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major

1 reference

https://api.crossref.org/works/10.3109%2F03630269.2011.576906

21 January 2018

Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia

1 reference

https://api.crossref.org/works/10.3109%2F03630269.2011.576906

21 January 2018

The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores

1 reference

https://api.crossref.org/works/10.3109%2F03630269.2011.576906

21 January 2018

Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging.

1 reference

https://api.crossref.org/works/10.3109%2F03630269.2011.576906

21 January 2018

A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients

1 reference

https://api.crossref.org/works/10.3109%2F03630269.2011.576906

21 January 2018

Identifiers

10.3109/03630269.2011.576906

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/21599442

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 February 2018

http://europepmc.org/abstract/MED/21599442

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48665941&oldid=2205990537"